scholarly journals Esophageal Leiomyoma and Simultaneous Overlying Squamous Cell Carcinoma: A Case Report and Review of the Literature

2020 ◽  
Author(s):  
Saadat Mehrabi ◽  
Mohammad Javad Yavari Barhaghtalab ◽  
Safoora Hejazinia ◽  
Hossein Saedi
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Esophageal Resection ◽  
Simultaneous Occurrence ◽  
Benign Tumors ◽  
Esophageal Leiomyoma ◽  
Epithelial Tumor ◽  
Carcinoma Of Esophagus ◽  
Esophageal Carcinomas

Abstract Background: Squamous cell carcinoma is the most common epithelial tumor of the esophagus. Upper endoscopy with multiple minimally invasive biopsies should be performed to confirm the diagnosis. Leiomyoma of esophagus is rare, but it’s the most common benign submucosal mesenchymal tumor of the esophagus. The simultaneous occurrence of an overlying epithelial lesion and a mesenchymal lesion is very rare. This study aims to show a case operated due to squamous cell carcinoma of esophagus that was postoperatively diagnosed with coexistent esophageal leiomyoma and provide a clear overview of the existing literature on it. Case presentation: The patient was a 41-year-old lady who underwent three field esophagectomy (McKeown). In reviewing the pathology slides, the patient had poorly differentiated squamous cell carcinoma and also multiple leiomyomas. A leiomyoma was coexisted with an invading overlying squamous cell carcinoma. Conclusion: It is concluded that esophageal carcinomas may coexist with leiomyomas; preexisting benign tumors may have played an important role in the development of carcinoma by inducing constant stimulation of the overlying mucosa; endoscopic ultrasonography is recommended to avoid overestimating the extent of tumor invasion and the resultant aggressive radical surgery; and esophageal resection is still the modality of choice in treatment in developing countries and also countries with limited equipment.

scholarly journals Esophageal leiomyoma and simultaneous overlying squamous cell carcinoma: a case report and review of the literature

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Saadat Mehrabi ◽  
Mohammad Javad Yavari Barhaghtalab ◽  
Safoora Hejazinia ◽  
Hossein Saedi
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Esophageal Resection ◽  
Simultaneous Occurrence ◽  
Benign Tumors ◽  
Esophageal Leiomyoma ◽  
Epithelial Tumor ◽  
Pathological Evaluation ◽  
Esophageal Carcinomas

Abstract Background Squamous cell carcinoma is the most common epithelial tumor of the esophagus. Upper endoscopy with multiple minimally invasive biopsies should be performed to confirm the diagnosis. Leiomyoma of esophagus is rare, but it’s the most common benign submucosal mesenchymal tumor of the esophagus. The simultaneous occurrence of an overlying epithelial lesion and a mesenchymal lesion is very rare. This study aims to show a case operated due to squamous cell carcinoma of esophagus that was postoperatively diagnosed with coexistent esophageal leiomyoma and give a clear overview of the existing literature on it. Case presentation The patient was a 41-year-old woman who underwent three field esophagectomy (McKeown). Pathological evaluation was done, and the patient had poorly differentiated squamous cell carcinoma and multiple leiomyomas. A leiomyoma was found with an invading overlying squamous cell carcinoma. Conclusion It is concluded that esophageal carcinomas may coexist with leiomyomas; preexisting benign tumors may have played an important role in the development of the carcinoma by inducing constant stimulation of the overlying mucosa; endoscopic ultrasonography is recommended to avoid overestimating the extent of tumor invasion and the resultant aggressive radical surgery. As the developing countries had limited equipment, esophageal resection could be the modality of choice in the treatment.

scholarly journals Alpha-1 Antitrypsin Deficient Squamous Cell Carcinoma of Esophagus in the Azeri Population of Iran

2010 ◽  
Vol 41 (10) ◽  
pp. 613-618 ◽  
Author(s):  
Shahla Mohammad Ganji ◽  
Abbas Sahebghadam-Lotfi ◽  
Ferdous Rastgar-Jazii ◽  
Mansour Yazdanbod ◽  
Ali Mota ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Carcinoma Of Esophagus ◽  
Alpha 1 Antitrypsin

Immunohistochemical Study of Esophageal Carcinomas Other Than Squamous Cell Carcinoma

1993 ◽  
pp. 502-506
Author(s):  
Yoshihisa Morisaki ◽  
Shingo Shima ◽  
Yutaka Yoshizumi ◽  
Yoshiaki Sugiura ◽  
Susumu Tanaka
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Immunohistochemical Study ◽  
Esophageal Carcinomas

Phase II randomized study comparing concurrent chemoradiation versus neoadjuvant chemotherapy followed by chemoradiation in locally advanced unresectable squamous cell carcinoma of esophagus.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15138-e15138
Author(s):  
Pritee Baburao Chaudhari ◽  
Subhash Chander ◽  
B. K. Mohanti ◽  
Atul Sharma ◽  
Jaspreet Kaur ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Post Treatment ◽  
Concurrent Chemoradiation ◽  
Weekly Paclitaxel ◽  
Carcinoma Of Esophagus

e15138 Background: A significant number of patients diagnosed with esophageal cancer (EC) presents with locally advanced disease. Nonsurgical curative therapy for unresectable EC has limited outcome. Methods: Phase II randomized control trial to assess early locoregional response (LRR) to neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiation (CRT) versus definitive CRT in surgically unresectable squamous cell carcinoma of esophagus (ESCC). A total of 30 patients were randomly assigned to two arms. Arm 1: 2 cycles NACT regimen of 5-fluorouracil (750mg/m2 D1-4) and cisplatin (80mg D1-2) followed by CRT, radiation of 56Gy/ 28 Fr concurrent with weekly paclitaxel 50mg/m2 and carboplatin AUC2. Arm2: CRT; consisting of radiation 56Gy/28Fr and weekly paclitaxel 50mg/m2 and carboplatin AUC2. All the patients were followed till 6 months post treatment. LRR assessment was done at 1, 3 and 6 months post treatment. Wilcoxon multivariate analysis was carried out and difference of the factors were assessed by chi square test (x2 p<0.05). Results: Mean age in two arms were 52 and 54 years respectively. The study had median follow up of 6.6 months. Conclusions: In unresectable EC, CRT showed higher LRR, treatment completion and lesser toxicity compared to NACT combined with CRT. In this pilot cohort of locally advanced unresectable EC paclitaxel and carboplatin combined with radiotherapy has good tolerance and compliance. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document